Fast-internalizing Receptor-based Bispecific ADCs
Fast-internalizing Receptor-based Bispecific ADCs
Fast-internalizing receptor-based bispecific ADCs (Antibody-Drug Conjugates) are emerging as a powerful therapeutic strategy in cancer treatment. These innovative drugs leverage the rapid internalization of receptors to deliver potent cytotoxic agents directly to tumor cells, improving treatment efficacy while minimizing off-target effects. The development of Fast-internalizing Receptor-based Bispecific ADCs is transforming the landscape of oncology therapies, offering new hope for patients with previously resistant forms of cancer.
What's Your Reaction?






